Clinical trial
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
NCT05089643
Study timeline
Study start (actual)2019-04-11Date precision: day
Registry last updated2022-01-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Triple-Negative Breast Cancerunresolved
Interventions
AnlotinibDRUG
CapecitabineDRUG · verified · RxNorm: capecitabine
Sponsors & collaborators
Chinese Academy of Medical Scienceslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05089643 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.